ORAL GNRH ANTAGONIST SHR7280 FOR THE PREVENTION OF PREMATURE LUTEINIZING HORMONE (LH) SURGE IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION (COH) IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART)

Hongbin Chi,Ying Song,Lei Jin,Xueru Song,Xiaohong Wang,Qianhong Ma,Yunxia Cao,Xiaoyan Liang,Lingyu Ma,Yuqi Sun,Chang Shu,Hong Chen

DOI: https://doi.org/10.1016/j.fertnstert.2023.08.357

IF: 6.7

2023-01-01

Fertility and Sterility

Abstract:Gonadotropin-releasing hormone (GnRH) antagonists have been shown to effectively prevent premature LH surge. This study aimed to evaluate the efficacy and safety of SHR7280, a novel small-molecule oral GnRH antagonist, in inhibiting premature LH surge in women undergoing COH in ART. This multicenter, open-label, dose-finding, phase 2 trial (NCT05082233) enrolled infertile women aged 20-39 years for whom in vitro fertilization or intracytoplasmic sperm injection was indicated. The starting dose of SHR7280 was 300 mg BID, followed by dose exploration in two lower dose groups (200 mg BID and 200 mg QD) sequentially. If an LH surge (LH >10 IU/L) occurred, the trial would be terminated in that dose group. SHR7280 was administrated orally on D5 of Gonal-F stimulation until hCG administration when ≥3 follicles with a diameter ≥17 mm or ≥2 follicles with ≥18 mm were observed. The primary endpoint was the rate of premature LH surge inhibition during SHR7280 treatment. A total of 85 patients received SHR7280 treatment (40 patients with 300 mg BID, 42 patients with 200 mg BID, and 3 patients with 200 mg QD) and the mean duration of exposure to SHR7280 was 5.7±1.2, 5.7±1.3, and 3.7±0.6 days (mean±SD), respectively. During SHR7280 treatment, 1 patient in the 200 mg QD group experienced a premature LH surge, yielding a rate of LH surge inhibition of 98.8% (84/85) in the study population. The mean number of oocytes retrieved in each patient was 10.3±4.9. The mean number of two pronuclei (2PN) oocytes that emerged 16-18h after fertilization was 6.3±3.0 and the mean number of embryos with grade I-II quality on D3 after fertilization was 3.9±2.4. Among the 71 patients who underwent fresh embryo transfer, 44 patients (62.0%, 95% CI 49.7-73.2) tested positive for serum β-hCG between D13-15 after embryo transfer and 38 (53.5%, 95% CI 41.3-65.5) were confirmed to be clinically pregnant. The mean total dose of Gonal-F was 1561.9±421.6 IU, with a mean duration of treatment lasting 8.8±1.4 days. The mean serum estradiol concentration on the day of hCG injection was 1620.1±940.5 pg/mL. No spontaneous ovulation occurred on the day of oocyte retrieval. Of the 85 patients, 37 (43.5%) experienced adverse events (AEs), the majority of which were mild in severity (29 [34.1%]). The most common AEs were premature labor (6 [7.1%]) and threatened abortion (5 [5.9%]). Two (2.4%) patients experienced treatment-related AEs. The drug exposure decreased with the decreasing dose and frequency of SHR7280 administration. The mean LH level on the day of hCG administration was 1.1±0.7, 2.0±1.6, 2.2±0.4 IU/L in the 300 mg BID, 200 mg BID, and 200 mg QD group, respectively. The use of SHR7280 in women undergoing COH for ART was associated with a high rate of early LH surge suppression, high quality embryos, and a high clinical pregnancy rate. The recommended minimum effective dose for early LH surge inhibition was 200 mg BID. SHR7280 was well-tolerated and safe.